Replies to post #96026 on Biotech Values

[masterlongevity]

Lilly AD

just to note, if this product gets approval (which should be in 2013), it will have been a 9 yr gap since any new AD therapy has been approved.

AD is now the holy grail for pharmaceutial companies due to the size of the market and the dearth of treament options